MS Program - Recent Publications (2008)

Burton JM, Kimball S, Veith R, Bar-Or A, Dosch HM, Cheung R, Gagne D, Ursell  M, D’Souza C, O’Connor P.  A Phase I/II Dose-Escalation Trial of Vitamin D3 and Calcium in Multiple Sclerosis.  in press.
 
Burton JM, Bell CM, Walker SE, O’Connor P.  A case series of 4-Aminopyridine toxicity with unintentional overdose in patients with multiple sclerosis). Neurology, 2008; 71(22): 1833-1834.

Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus Intravenous Steroids for Treatment of Relapses in Multiple Sclerosis. (Protocol) Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD006921. DOI: 10.1002/14651858.CD006921.

Burton JM, O’Connor P.  Novel Oral Agents for Multiple Sclerosis.  Curr Neurol Neurosci Rep, 2007; 7(3): 223-230.

Burton JM, O’Connor P.  Multiple Sclerosis: Chapter 8 - Multiple Sclerosis clinical trial design and analysis.  Continuum, December 2004; 173-196.

Burton JM, Kern RZ, Halliday W, Mikulis D, Brunton J, Pepperell C, Jaigobin C.   Neurological manifestations of West Nile Virus infection.  Can J Neuol Sci 2004; 31: 185-193.

Costello F, Hodge W, Pan YI, Metz L, Kardon R.  Retinal Nerve Fiber Layer and Future Risk of Multiple Sclerosis.  Canadian Journal of Neurological Sciences 2008 Sept 35: 482-487.

Frohman EM, Costello F, Stuve O, Calabresi P, Miller DH, Hickman SJ, Sergott R, Conger A, Salter A, Krumwiede KH, Frohman TC, Balcer L, Zivadinov R.  Modeling axonal degeneration within the anterior visual system:  implications for demonstrating neuro-protection in multiple sclerosis.  Arch Neurol. 2008 Jan; 65(1): 26 – 35

Giovannoni G, Barbarash O, Casset-Semanaz F, King J, Metz L, Pardo G, Simsarian J, Soelberg Sørensen P, Stubinski B; on behalf of the Rebif® New Formulation Study Group. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Multiple Sclerosis Mult Scler. 2008 Aug 28. [Epub ahead of print]

Pepperell, C, Rau N, Krajden S, Kern R, Humar A, Mederski B, Simor A, Low DE, McGeer A, Mazzuli T, Burton J, Jaigobin C, Fearon M, Artsob H, Drebot MA, Halliday W, Brunton J.  West Nile virus infection in 2002:  Morbidity and mortality among patients admitted to hospital in southcentral Ontario.  CMAJ  2003; 168: 1399-1414.

Patten SB, Williams JV, Metz L. Antidepressant Use in Association with Interferon and Glatiramer Acetate Treatment in Multiple Sclerosis. Mult Scler. 2008 Apr;14(3):406-11. Jan 31 [Epub ahead of print

Zhang Y, Metz LM, Yong VW, Bell RB, Yeung M, Patry DG, Mitchell JR. Pilot study of minocycline in relapsing-remitting multiple sclerosis. Can J Neurol Sci. 2008 May;35(2):185-191

O'Connor P, Devonshire V; Canadian Network of MS Clinic (Patry DG). The use of disease-modifying agents in multiple sclerosis-by the Canadian Network of MS Clinics.